RNS Number : 9125R
Genus PLC
20 June 2018

For Immediate Release **20 June 2018**

Genus plc

('Genus', the 'Company' or the 'Group')

Capital Markets Event

Genus, a leading global animal genetics company, is holding a Capital Markets Event today at 2pm at which no material new information will be disclosed and Genus will not be commenting on current trading.

The Capital Markets Event will cover Genus's business model and the initiatives being implemented to further strengthen its leadership in the animal genetics market. The presentations given by Genus's management will be made available on the Company website tomorrow.

For further information please contact:

Genus plc Tel: 01256 345970

Karim Bitar, Chief Executive

Stephen Wilson, Group Finance Director

Buchanan Tel: 0207 466 5000

Charles Ryland/ Chris Lane/ Sophie Wills

This announcement will be available on the Genus website, www.genusplc.com

About Genus

Genus is a world-leading animal genetics company. We continuously produce better breeding livestock with desirable characteristics, which helps farmers to produce better quality meat and milk more efficiently and sustainably. We do this by analysing animals' DNA to select those with desirable characteristics, and then breed successive generations from those animals. We also own technology to screen and process semen for desirable traits, such as gender, and license technology to make precise, desirable gene edits to animals' DNA.

Genus's worldwide sales are made in over seventy countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in production.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, proprietary technology and knowhow used to improve them, relationships with leading meat and milk producers, and its global supply chain and distribution networks.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCBUGDLRUBBGIC